Both systems are crucial in promoting tumor growth and proliferation: CTLA-4 is competitive for the costimulatory binding CD80/86-CD28 and its binding to CD80/86 generates a negative signal which is responsible for immune cell inactivation. Here, CTLA4 is linked to neoplasm.